media – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

【EXPERT Q&A】A Buyer Asked for Free Samples in the First Inquiry. Should You Send Them Right Away?

Drugdu.com expert’s response: If you’re working in the pharmaceutical or medical device export business, you’ve probably seen inquiries like this: Before discussing pricing or technical details, the buyer simply asks: “Can you provide free samples?” Some suppliers see this as a positive signal. They assume the buyer is ready to evaluate the product and hope that sending samples quickly will increase the chance of winning the order. Others become cautious immediately, worrying that the buyer is only looking for free samples with no real purchasing intention. In reality, both conclusions may be premature. A sample request shows that the buyer is interested enough to evaluate the product, but it doesn’t tell you why they need the sample, what they intend to do with it, or whether a commercial order is likely to follow. Instead of rushing to ship samples, it’s usually more valuable to clarify the buyer’s requirements first. ...
- Source: drugdu
- 33
- September 18, 2026
Novartis acquires Sironax’s blood-brain barrier delivery platform for $125 million

On September 16, Novartis announced the acquisition of biotechnology company Sironax for $125 million, gaining access to its proprietary blood-brain barrier (BBB) delivery platform technology. Sironax’s platform utilizes receptor-mediated transcytosis to efficiently deliver large molecule drugs (such as antibodies and gene therapies) into the central nervous system, addressing the longstanding challenge of large molecules being unable to cross the BBB. The technology platform is expected to significantly enhance Novartis’ drug development capabilities in central nervous system diseases, including Alzheimer’s disease, Parkinson’s disease, and neuro-oncology. This acquisition continues Novartis’ recent strategic investments in neuroscience and rare diseases. Blood-brain barrier delivery technology is considered a key enabling technology for next-generation CNS drug development. Source: https://tldrbio.tech/
- Source: drugdu
- 46
- September 17, 2026
IASO Bio’s in vivo CAR-T IASO208 receives FDA clinical trial clearance

On September 16, IASO Biotherapeutics announced that its investigational new drug application for IASO208, a CD20-targeting in vivo CAR-T product developed on its proprietary InTelliCAR platform, has received FDA clearance in the U.S. As the first lentiviral vector-based in vivo CAR-T product from China to receive FDA IND clearance, IASO208 will directly proceed to a Phase Ib study based on Chinese investigator-initiated trial data, targeting relapsed/refractory B-cell non-Hodgkin lymphoma. In vivo CAR-T is a next-generation cell therapy technology that eliminates the need for ex vivo T cell engineering, instead delivering vectors directly in patients to generate CAR-T cells in vivo. This approach has the potential to dramatically reduce treatment costs and timelines, moving cell therapy toward “off-the-shelf.” The FDA clearance for IASO208 signifies that China is competing on par with the international community in the in vivo CAR-T space, further deepening IASO Biotherapeutics’ internationalization in cell therapy. Source: http://m.toutiao.com/group/7686078944797311529/
- Source: drugdu
- 47
- September 17, 2026
NMPA accepts marketing registration application for Velsipity domestic manufacturing transfer

On September 17, Everest Medicines announced that CDE of the NMPA has accepted the marketing registration application for Velsipity (etrasimod arginine tablets) for the transfer of manufacturing from overseas to domestic production, and has granted Priority Review. Local production is expected to commence in 2027. Velsipity was approved by NMPA in February 2026 for adult patients with moderate to severe active ulcerative colitis (UC) who have an inadequate response, loss of response, or intolerance to conventional therapies or biologics. Source: https://finance.eastmoney.com/a/202609173876680142.html
- Source: drugdu
- 46
- September 17, 2026
Ziprasidone mesylate from SSY Group has been approved for registration as an active pharmaceutical ingredient.

On September 16, SSY Group announced that its ziprasidone mesylate has been approved by the NMPA of China for registration as an API used in marketed formulations. Ziprasidone mesylate is primarily used to treat acute agitation symptoms in patients with schizophrenia. According to the announcement, SSY Group has built a leading second-generation antipsychotic HPAPI platform in China, covering blonanserin, lurasidone, ziprasidone hydrochloride, and the newly approved ziprasidone mesylate. Source: https://finance.eastmoney.com/a/202609163876154835.html
- Source: drugdu
- 38
- September 17, 2026
Kanghong Pharmaceutical’s research on Shugan Jieyu Capsules won the first prize of the Science and Technology Award of the Chinese Pharmaceutical Association.

The 21st Chinese Pharmaceutical Association Science and Technology Award was presented at the 2026 Chinese Pharmaceutical Congress. The project “New Drug Creation and Industrial Innovation for Antidepressants Combining Traditional Chinese Medicine Syndromes,” in which Kanghong Pharmaceutical played a significant role, won the first prize. The Chinese Pharmaceutical Association Science and Technology Award was officially approved by the Ministry of Science and Technology in July 2005. It is sponsored by the Chinese Pharmaceutical Association and recognizes researchers and innovative achievements that have made major breakthroughs in pharmaceutical science. It is a highly prestigious and influential award in the domestic pharmaceutical field. Kanghong Pharmaceutical’s Shugan Jieyu Capsules are the core landmark achievement of this award-winning project. As the first approved traditional Chinese medicine for mild to moderate depression in China, this product is a Class II protected TCM variety and was recently included in the National Essential Medicines List (2026 Edition). Since ...
- Source: drugdu
- 36
- September 17, 2026
Johnson & Johnson celebrates the launch of Rybrevant FASPRO (amivantamab subcutaneous injection) in China

As China’s first and currently only approved subcutaneous injection formulation for the treatment of EGFR-mutant advanced non-small cell lung cancer, Rybrevant FASPRO reduces the administration time from several hours with traditional intravenous infusion to just minutes, and significantly reduces the risk of infusion-related adverse reactions. Johnson & Johnson today announced the official launch of Rybrevant FASPRO (amivantamab injection, subcutaneous) in China, in combination with LECLIZE (lazertinib mesylate tablets) for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletion or exon 21 L858R substitution mutation. Rybrevant FASPRO is the first and currently only subcutaneous injection formulation approved in China for the treatment of patients with EGFR-mutant advanced NSCLC. Combined with lazertinib, it demonstrates significant ease of administration in first-line combination therapy, reducing administration time from several hours to just minutes. In terms of safety, compared with the intravenous formulation, Rybrevant ...
- Source: drugdu
- 38
- September 17, 2026
First! Novartis’ blockbuster generic radiopharmaceutical receives approval

On September 14, Curium announced that Bexlutry ([177lu]oxooctreotide, development code: PNT2003) had received FDA approval. This drug is Lutathera ([177lu]oxooctreotide), i.e., a generic version. This is the world’s first approved generic radiopharmaceutical. The original drug, Lutathera, is a radioligand therapy (RLT) targeting the somatostatin receptor type 2 (SSTR2), acquired by Novartis through its acquisition of Advanced Accelerator Applications. It was first approved for marketing in the European Union in 2017. Currently, the drug is indicated for adult patients and children aged 12 years and older with unresectable or metastatic, progressive, well-differentiated (G1 and G2) SSTR-positive gastroenteropancreatic neuroendocrine tumors (GEP-NET). According to Novartis’ financial report, Lutathera’s global sales were $816 million in 2025. In November 2022, Lantheus acquired exclusive global rights to PNT2003 from POINT Biopharma, excluding China, Japan, South Korea, Indonesia, and Singapore. In October 2023, Eli Lilly acquired POINT Biopharma for $1.4 billion, gaining the remaining rights to the ...
- Source: drugdu
- 38
- September 17, 2026
the Uzbekistan Medical Devices Exhibition

Organiser：IEG Exhibition Company Time：September 15th – 17th, 2026 Address：Amir Temur Street, Tashkent, 700084107, Uzbekistan Exhibition hall：Uzekspocentre Exhibition Centre Product range: Medical Equipment: Medical electronic instruments, ultrasound instruments, X-ray equipment, medical optical instruments, clinical laboratory analytical instruments, dental equipment and materials, hemodialysis equipment, anesthesia and respiratory equipment, disposable medical supplies, dressings and hygiene materials, surgical instruments, hospital beds, operating tables, operating table spotlights, examination beds, dental chairs, in-hospital furniture Medical Supplies: Medical electronic instruments, medical ultrasound instruments, medical X-ray equipment, medical optical instruments, clinical laboratory analytical instruments, dental equipment and materials, operating room equipment and appliances, emergency room equipment and appliances, diagnosis room equipment and appliances, diagnostic equipment and supplies, medical health care equipment and supplies, traditional Chinese medical instruments and rehabilitation devices, home health care products, small household diagnostic instruments, home monitoring instruments, home therapeutic instruments, rehabilitation instruments and supplies, physiotherapy instruments and supplies, electronic medical instruments, dental tools, ...
- Source: drugdu
- 42
- September 17, 2026
【EXPERT Q&A】How are in vitro diagnostic kits developed?

Drugdu.com expert’s response: The R&D of in vitro diagnostic kits is a rigorous and standardized full-process system, with 5 core key stages that ultimately produce safe and effective products complying with regulatory requirements. Stage 1: Project Initiation and Preparation Clarify the target analyte to be tested, intended use and application scenarios, and complete research on market capacity, competing products and clinical demands. Confirm technical feasibility through literature review, form the project team, and prepare the project initiation assessment document for review and approval. Define core indicators such as product performance parameters and intended use, complete design input, and form the product summary materials required for registration. Stage 2: Product Development Raw material screening: Select no less than 3 qualified suppliers to ensure the quality of core raw materials (antigens, antibodies, primers, probes, etc.) is stable and traceable. Process and system optimization: Determine key parameters such as reagent formulation ratio, reaction ...
- Source: drugdu
- 46
- September 16, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.